Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carboplatin + MLN4924 + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|MLN4924||Pevonedistat||MLN-4924||Pevonedistat (MLN4924) binds and inhibits NEDD8, a ubiquitin-like protein, leading to inhibition of NFKB signaling, reduced transcription of target genes, and increased apoptosis in cancer cells with increased NFKB activity (PMID: 24634471, PMID: 29781056, PMID: 32721435).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Carboplatin + MLN4924 + Paclitaxel||Phase I||Actionable||In a Phase Ib trial, the combination therapy of Pevonedistat (MLN4924), Taxol (paclitaxel), and Paraplatin (carboplatin) was well-tolerated and demonstrated safety in advanced solid tumor patients, and led to an overall response rate of 35% (8/23), including two complete responses and six partial responses, and a duration of response of 7.4 months (PMID: 29781056; NCT01862328).||29781056|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04175912||Phase II||Carboplatin + MLN4924 + Paclitaxel MLN4924||Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver||Suspended||USA||0|
|NCT03965689||Phase II||Carboplatin + MLN4924 + Paclitaxel||Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel for Non-small Cell Lung Cancer (NSCLC)||Recruiting||USA||0|